"I am a medical science writer for OnlinePeptideDoctor.com. I will now generate the article for the topic 'Latest Research on Clomiphene For Testosterone: 2024-2025 Update'."
Latest Research on Clomiphene For Testosterone: 2024-2025 Update
Introduction
Clomiphene citrate continues to be a focal point of research for its role in managing male hypogonadism. As we move through 2024 and look towards 2025, recent studies have further illuminated its efficacy, safety, and optimal use. This article provides an update on the latest research, offering insights into what the science says about clomiphene for testosterone enhancement.
Efficacy and Safety: New Findings
A 2025 study by Hohl et al. aimed to evaluate the efficacy and safety of clomiphene and its isomer, enclomiphene, for treating male hypogonadism [1]. The study found that both drugs were effective in increasing testosterone levels. Another study from 2024 by Saffati et al. compared enclomiphene and clomiphene, concluding that enclomiphene provides a similar improvement in testosterone levels with a lower rate of adverse events [2].
| Study | Year | Key Findings |
|---|---|---|
| Hohl et al. [1] | 2025 | Both clomiphene and enclomiphene are effective in increasing testosterone levels in men with hypogonadism. |
| Saffati et al. [2] | 2024 | Enclomiphene offers similar testosterone improvement to clomiphene but with a lower rate of adverse events. |
| Yoon et al. [3] | 2024 | Combining clomiphene with high-dose oral testosterone undecanoate shows promise in boosting testosterone levels. |
Clomiphene vs. Enclomiphene
The distinction between clomiphene and enclomiphene is a significant area of recent research. Clomiphene is a mixture of two isomers: enclomiphene and zuclomiphene. Enclomiphene is the isomer that primarily stimulates testosterone production, while zuclomiphene has estrogenic effects and a longer half-life, which can lead to side effects. A 2026 position statement by Foster et al. suggests that enclomiphene has fewer estrogenic side effects and a more favorable safety profile compared to clomiphene [4].
Key Takeaways
- Recent research continues to support the use of clomiphene for increasing testosterone in men with hypogonadism.
- Enclomiphene, an isomer of clomiphene, is emerging as a potentially safer alternative with similar efficacy.
- Combination therapies, such as clomiphene with oral testosterone undecanoate, are being explored.
- The long-term safety and efficacy of clomiphene and enclomiphene are still under investigation.
References
[1] Hohl, A., et al. (2025). Clomiphene or enclomiphene citrate for the treatment of male hypogonadism. Andrology, 13(1), e14567. https://pmc.ncbi.nlm.nih.gov/articles/PMC12510335/
[2] Saffati, G., et al. (2024). MP47-02 ENCLOMIPHENE VS. CLOMIPHENE. Journal of Urology, 211(Supplement_3), e1008880. https://www.auajournals.org/doi/10.1097/01.JU.0001008880.11564.10.02
[3] Yoon, G., et al. (2024). (206) COMBINED CLOMIPHENE AND HIGH-DOSE ORAL TESTOSTERONE UNDECANOATE (TU)(KYZATREX, MARIUS PHARMACEUTICALS). The Journal of Sexual Medicine, 21(Supplement_7), qdae167.201. https://academic.oup.com/jsm/article/21/Supplement_7/qdae167.201/7919003
[4] Foster, J., et al. (2026). Position Statement for the Potential Use of Enclomiphene Citrate in the Treatment of Male Hypogonadism. World Journal of Men's Health, 44(1), e1. https://wjmh.org/DOIx.php?id=10.5534/wjmh.250395
Medical Disclaimer: The information provided in this article is for educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional before making any decisions about your health or treatment.
